Esperion Therapeutics ESPR Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred revenue?
- Esperion Therapeutics (ESPR) reported deferred revenue of $43.53M in Q1 2026.
- How has Esperion Therapeutics's deferred revenue changed year-over-year?
- Esperion Therapeutics's deferred revenue increased by 858.4% year-over-year, from $4.54M to $43.53M.
- What is the long-term trend for Esperion Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred revenue has grown at a 83.4% compound annual growth rate (CAGR), from $1.66M to $34.48M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.